{"gene":"TADA3","run_date":"2026-06-10T10:51:54","timeline":{"discoveries":[{"year":1993,"finding":"ADA3 (NGG1) was identified as a yeast gene whose mutations prevent toxicity of GAL4-VP16; double disruption of ada2 and ada3 showed no additive growth defect, placing ADA3 in the same pathway as ADA2. Selection of transcription initiation sites in vitro was altered in ada3 mutants, suggesting a role in the response to acidic activators.","method":"Genetic epistasis (double mutant analysis), in vitro transcription initiation assay","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis with double mutant and in vitro transcription assay, single lab","pmids":["8413201"],"is_preprint":false},{"year":1993,"finding":"NGG1 (ADA3) was identified as required for glucose repression of GAL4p-activated genes; its activity was GAL4-dependent and promoter analysis showed a correlation between the number of GAL4p binding sites and NGG1p activity, establishing a functional role in repression at GAL4-regulated promoters.","method":"Genetic screen, promoter deletion analysis, reporter assays in yeast","journal":"The EMBO journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and reporter assays, single lab, two complementary approaches","pmids":["8262068"],"is_preprint":false},{"year":1995,"finding":"ADA2, ADA3, and GCN5 form a heterotrimeric complex in vitro, with ADA2 serving as the linchpin holding ADA3 and GCN5 together. The C-terminal domain of ADA3 is sufficient for complex formation, while the N-terminal domain mediates interaction between activation domains and the ADA complex.","method":"In vitro reconstitution, domain deletion analysis, in vivo activation assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution of trimeric complex plus domain mapping, replicated in subsequent studies","pmids":["7862114"],"is_preprint":false},{"year":1996,"finding":"NGG1p/ADA3p requires residues 274-373 (including an amphipathic alpha-helix rich in Phe residues) for glucose repression. Single and double disruptions of ngg1 and ada2 had comparable effects on glucose repression, confirming they act in the same complex. An ADA2p-interaction site was mapped to residues 308-373 of NGG1p.","method":"Deletion mutagenesis, genetic epistasis, in vivo reporter assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — deletion mutagenesis with functional readout plus epistasis, single lab","pmids":["8621592"],"is_preprint":false},{"year":1997,"finding":"NGG1p/ADA3p and ADA2p are co-immunoprecipitated from yeast whole-cell extracts (less than 2% of ADA2p was not associated with NGG1p), and each protein's stability depends on the other. NGG1p-containing complexes of approximately 200 kDa, 900 kDa, and >2 MDa were resolved, and TBP co-immunoprecipitated with NGG1p in a manner requiring NGG1p residues 274-307.","method":"Co-immunoprecipitation, ion-exchange chromatography, gel filtration","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP with quantification, multiple chromatographic methods, replicated domain requirement","pmids":["9038164"],"is_preprint":false},{"year":1997,"finding":"ADA1 interacts with ADA3 and other ADA complex members as shown by partial purification and immunoprecipitation, and the ADA/GCN5 complex has an estimated molecular mass of approximately 2 MDa. ADA1 and ADA5 mutations produce more severe defects than ada2/ada3/gcn5 mutations, suggesting two functional classes within the complex.","method":"Partial complex purification, co-immunoprecipitation, genetic phenotypic analysis","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus genetic epistasis, single lab","pmids":["9154821"],"is_preprint":false},{"year":2001,"finding":"Yeast Ada2, Ada3, and Gcn5 form the catalytic core of ADA and SAGA HAT complexes; this trimeric core is necessary and sufficient for nucleosomal HAT activity and lysine specificity in vitro. Ada3 is necessary for Gcn5-dependent nucleosomal HAT activity in yeast extracts; Ada2 potentiates Gcn5 catalytic activity, while Ada3 facilitates nucleosomal acetylation and expanded lysine specificity.","method":"In vitro reconstitution of HAT activity with nucleosome substrates, yeast extract HAT assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted catalytic core in vitro with nucleosome substrate, multiple functional readouts","pmids":["11773077"],"is_preprint":false},{"year":2001,"finding":"hADA3 physically interacts with p53 in human cells; this interaction is enhanced after DNA damage due to phosphorylation of the p53 N-terminus. hADA3 is required for full p53 transcriptional activity and p53-mediated apoptosis, and was identified as a component of histone acetyltransferase complexes.","method":"Yeast p53 dissociator assay, co-immunoprecipitation in human cells, functional transcription and apoptosis assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP, genetic interaction screen, functional transcription and apoptosis assays in human cells","pmids":["11707411"],"is_preprint":false},{"year":2002,"finding":"hADA3 binds selectively to high-risk HPV E6 proteins (not low-risk) and is targeted for E6-induced degradation. HPV E6 mutants that cannot degrade p53 but can interact with hADA3 abrogate p53-mediated transactivation and G1 arrest after DNA damage, revealing a p53-degradation-independent mechanism of p53 inactivation via hADA3.","method":"Co-immunoprecipitation, protein degradation assays, transcriptional reporter assays, cell cycle analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP, degradation assays with E6 mutants, functional p53 assays, multiple orthogonal approaches","pmids":["12138191"],"is_preprint":false},{"year":2002,"finding":"hADA3 directly binds RXRalpha in vitro and in vivo, and is part of activator complexes bound to native RXR response elements within the p21 promoter as shown by chromatin immunoprecipitation. hADA3 enhances RXRalpha-mediated transactivation of retinoid target genes, and HPV E6 inhibits this RXRalpha-mediated transactivation by targeting hADA3.","method":"In vitro binding assay, co-immunoprecipitation, chromatin immunoprecipitation, transcriptional reporter assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vitro direct binding, ChIP at native promoter, functional reporter assay, multiple orthogonal methods","pmids":["12235159"],"is_preprint":false},{"year":2002,"finding":"Mouse mADA3-containing TFTC (TBP-free-TAF-containing) complex interacts with ERalpha in a ligand-independent manner; mADA3 itself does not directly interact with nuclear receptors despite containing two LxxLL NR boxes, indicating other complex subunits mediate the interaction.","method":"Co-immunoprecipitation, cloning and characterization of mouse ADA3","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP of complex with ER, direct binding test (negative for mADA3 alone), single lab","pmids":["12034840"],"is_preprint":false},{"year":2004,"finding":"hADA3 directly interacts with ERalpha and ERbeta; hADA3 is a component of activator complexes bound to the native ER response element in the pS2 promoter (shown by ChIP); RNA interference-mediated knockdown of endogenous hADA3 inhibited ER-mediated transactivation and estrogen-induced expression of pS2, cathepsin D, and progesterone receptor.","method":"Co-immunoprecipitation, chromatin immunoprecipitation, RNA interference, transcriptional reporter assay, RT-PCR","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct binding, ChIP at native promoter, endogenous knockdown with multiple target gene readouts","pmids":["15496419"],"is_preprint":false},{"year":2007,"finding":"hAda3 stabilizes p53 protein by promoting its acetylation at p300/CBP sites; hAda3-dependent acetylation is required for increased p53 stability and target gene induction. Endogenous hAda3 is essential for DNA damage-induced acetylation and stabilization of p53, placing hAda3 as a component of p300/CBP-containing coactivator complexes that mediate p53 acetylation.","method":"shRNA knockdown, inducible overexpression, site-directed mutagenesis of p53 acetylation sites, co-immunoprecipitation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (knockdown, OE, mutagenesis, co-IP), replicated across prior and current lab findings","pmids":["17272277"],"is_preprint":false},{"year":2007,"finding":"p14ARF-induced senescence requires hAda3; expression of the N-terminal domain of hAda3 (which binds p53 but not p300) blocked p14ARF-induced p53 acetylation and senescence. hAda3 overexpression increased p300-mediated p53 acetylation, and siRNA knockdown decreased p53 acetylation and p21cip1 accumulation in response to p14ARF.","method":"Domain expression (N-terminal fragment), siRNA knockdown, HPV16 E6 mutant Y54D selective degradation, p53 acetylation assays","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — domain dissection identifying separable p53-binding and p300-binding functions, siRNA knockdown, selective E6 mutant validation","pmids":["17452980"],"is_preprint":false},{"year":2007,"finding":"Ada3, ERalpha, and three HATs (p300, PCAF, and Gcn5) are present in a complex demonstrated by glycerol gradient cosedimentation and immunoprecipitation. shRNA-mediated knockdown of Ada3 in ER-positive breast cancer cells significantly reduced ligand-dependent recruitment of p300, PCAF, and Gcn5 to the ER-responsive pS2 promoter, and Ada3 is critical for estrogen-dependent proliferation.","method":"Glycerol gradient cosedimentation, co-immunoprecipitation, chromatin immunoprecipitation, shRNA knockdown, 2D/3D proliferation assays","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods; ChIP demonstrates functional requirement for HAT recruitment; shRNA with proliferation phenotype","pmids":["18089809"],"is_preprint":false},{"year":2007,"finding":"hADA2a and hADA3 physically interact with beta-catenin through its Armadillo repeats 6-12 and C-terminal transactivation domain; both proteins reside with beta-catenin at the c-Myc enhancer. RNAi-mediated reduction of hADA2a and hADA3 results in reduced beta-catenin acetylation, reduced reporter activity, and reduced activation of endogenous Wnt target genes.","method":"Co-immunoprecipitation, chromatin immunoprecipitation, RNA interference, transcriptional reporter assays, domain mapping","journal":"Cancer biology & therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP with domain mapping, ChIP, and RNAi functional assays, single lab","pmids":["18059173"],"is_preprint":false},{"year":2007,"finding":"Drosophila dADA3 localizes to chromosomes and its levels are significantly reduced in dGcn5 and dAda2a (but not dAda2b) mutant backgrounds. dAda3 mutants show reduced acetylation specifically at histone H3 K9 and K14 (not K18) and H4 K12 (not K5, K8, K16), and reduced H3 S10 phosphorylation also seen in dGcn5 mutants. dADA3 is required for oogenesis and somatic cell viability.","method":"Genetic mutant analysis, immunostaining for histone modifications, localization studies, genetic interaction","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic loss-of-function in Drosophila with specific histone modification readouts, ortholog confirmed by functional conservation","pmids":["17967867"],"is_preprint":false},{"year":2008,"finding":"ANCO-1 and ANCO-2 interact with ADA3; the interaction occurs between the conserved C-terminal domain of ANCO-1 and the N-terminal transactivation domain of ADA3. ANCO-1 colocalizes with ADA3, ADA2alpha/beta, and PCAF at nuclear dots in vivo. ANCO-1 and ANCO-2 repress ADA3-mediated transcriptional co-activation on nuclear receptors, while ANCO-1 stimulates p53-mediated transactivation.","method":"Co-immunoprecipitation, domain mapping, immunofluorescence co-localization, transcriptional reporter assay","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — co-IP with domain mapping and functional reporter assay, single lab","pmids":["18377363"],"is_preprint":false},{"year":2008,"finding":"HPV16 E6 mutants that degrade hAda3 but not p53 abrogate p14ARF-induced growth arrest and efficiently immortalize mammary epithelial cells despite normal p53 levels, establishing that hAda3 degradation (not only p53 degradation) is sufficient for inactivation of the p14ARF-p53 pathway.","method":"HPV16 E6 mutant analysis, protein degradation assays, cell proliferation/immortalization assays","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional E6 mutant panel with clear mechanistic separation of hAda3 vs. p53 degradation, single lab","pmids":["18256148"],"is_preprint":false},{"year":2009,"finding":"HPV16 E6-induced degradation of hADA3 in cervical carcinoma cells is E6AP-dependent; siRNA knockdown of E6 or E6AP increased hADA3 protein levels, decreased cellular proliferation, and increased apoptotic rate.","method":"siRNA knockdown, protein expression analysis, proliferation and apoptosis assays","journal":"Cancer investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA with multiple phenotypic readouts, single lab","pmids":["19194825"],"is_preprint":false},{"year":2010,"finding":"hADA3 interacts directly with RARalpha in a hormone-dependent manner through its LxxLL motifs engaging the receptor coactivator pocket; loss- and gain-of-function mutations in LxxLL motifs and the receptor coactivator pocket confirmed this mechanism. hADA3 associates with RARalpha target gene promoters in a hormone-dependent manner, and ADA3 knockdown impairs RARbeta2 expression.","method":"Co-immunoprecipitation, site-directed mutagenesis (LxxLL motifs and receptor coactivator pocket), chromatin immunoprecipitation, siRNA knockdown, structural modeling","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct binding confirmed by mutagenesis of both partners (LxxLL and coactivator pocket), ChIP at native promoter, functional gene expression readout","pmids":["20413580"],"is_preprint":false},{"year":2012,"finding":"Germline deletion of Ada3 in mouse is embryonic lethal; conditional deletion in MEFs causes severe proliferation defect, G1-to-S delay due to accumulation of CDK inhibitor p27 (an indirect effect of Ada3-regulated c-Myc transcription), mitotic defects, and drastic changes in global histone acetylation.","method":"Germline and conditional knockout mouse, adenovirus-Cre deletion of Ada3(FL/FL) MEFs, rescue by human Ada3 expression, cell cycle analysis, microarray, histone modification analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean conditional KO with multiple orthogonal readouts (cell cycle, histone acetylation, gene expression), genetic rescue, mouse embryo lethality","pmids":["22736770"],"is_preprint":false},{"year":2012,"finding":"Ada3 deletion leads to increased markers of DNA damage (pATM, gammaH2AX, p53BP1, pRAD51) in untreated cells and a significant delay in disappearance of DNA damage foci after ionizing radiation. Ada3-null cells show enhanced chromosomal aberrations (breaks, fragments, deletions, translocations), establishing Ada3 as required for the DNA repair process and genomic stability.","method":"Conditional Ada3 knockout (adenovirus-Cre in Ada3(fl/fl) MEFs), immunofluorescence for DNA damage markers, chromosomal aberration analysis, comet assay","journal":"Cell cycle","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean conditional KO with multiple DNA damage marker readouts and cytogenetic analysis, same genetic system replicated from prior study","pmids":["23095635"],"is_preprint":false},{"year":2013,"finding":"Three novel hADA3-interacting partners were identified by yeast two-hybrid: AATF (apoptosis-antagonizing transcription factor), PPP1R7 (PP1 regulatory subunit), and PPP2R5D (PP2A regulatory subunit). The C-terminal ADA2-interacting domain of hADA3 was not required for these interactions. Co-localization and co-immunoprecipitation in human cells confirmed the interactions.","method":"Yeast two-hybrid screen, co-immunoprecipitation, fluorescence microscopy, transcriptional reporter assay","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — yeast two-hybrid identified, validated by co-IP and co-localization, functional reporter assay, single lab","pmids":["23167988"],"is_preprint":false},{"year":2014,"finding":"PCAF and ADA3 regulate granzyme B-mediated Bid cleavage upstream of mitochondrial membrane permeabilization; knockdown of PCAF or ADA3 reduced PACS2 expression, and PACS2 knockdown phenocopied the PCAF/ADA3 knockdown effect on Bid processing and cytochrome c release, placing ADA3-PCAF upstream of PACS2 in the granzyme B apoptosis pathway.","method":"shRNA screen, siRNA knockdown, cytochrome c release assay, Bid cleavage assay, genetic epistasis by PACS2 knockdown","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 2 / Strong — functional genetic screen validated by siRNA, epistasis established by phenocopy, multiple orthogonal apoptosis readouts","pmids":["24464226"],"is_preprint":false},{"year":2014,"finding":"HPV16 E6 targets hADA3 for ubiquitin-mediated degradation via E6AP ubiquitin ligase; hADA3 undergoes SUMOylation that is accelerated in the presence of HPV16E6 and makes hADA3 unstable. Depletion of Ubc9 (SUMO E2 enzyme) prevented rapid hADA3 degradation, establishing that SUMOylation precedes and promotes E6-mediated ubiquitination of hADA3.","method":"Co-immunoprecipitation, ubiquitination assay, SUMOylation assay, Ubc9 depletion, protein stability assays","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple biochemical assays (ubiquitination, SUMOylation, E2 depletion), mechanistic ordering established, single lab","pmids":["24795430"],"is_preprint":false},{"year":2015,"finding":"ADA3 associates with the higher-order repeat region of alpha-satellite DNA on human X chromosome centromeres, and directly interacts with centromere protein CENP-B through its N-terminus (shown by proximity ligation assay, immunofluorescence, and deletional analysis). Knockdown of ADA3 decreased CENP-B loading onto centromeres, and a CENP-B binding-deficient ADA3 mutant failed to rescue cell proliferation in Ada3-deleted MEFs.","method":"Proximity ligation assay, immunofluorescence, deletion mutagenesis, ChIP on alpha-satellite DNA, CENP-B loading assay, proliferation rescue assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal localization methods, domain mapping, functional rescue with binding-deficient mutant","pmids":["26429915"],"is_preprint":false},{"year":2016,"finding":"ADA3 is acetylated in a cell cycle-dependent manner by GCN5, PCAF, and p300; SIRT1 is identified as a deacetylase that opposes this acetylation. Mass spectrometry and site-directed mutagenesis identified major acetylation sites. Acetylation-defective ADA3 mutants could interact with HATs but failed to restore global or locus-specific histone acetylation or cell proliferation in Ada3-deleted MEFs, establishing that ADA3 acetylation is functionally required.","method":"Mass spectrometry, site-directed mutagenesis, co-immunoprecipitation, HAT activity assays, rescue of Ada3-deleted MEFs","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — MS identification of sites, mutagenesis, functional rescue assay with acetylation-defective mutants, writer/eraser identification","pmids":["27402865"],"is_preprint":false},{"year":2017,"finding":"AKT activation downstream of EGFR/HER2 promotes phosphorylation of p300, which in turn promotes acetylation of ADA3. Lapatinib-mediated inhibition of HER1/HER2 reduced phospho-AKT, p300 phosphorylation, and ADA3 protein levels in a proteasome-dependent manner. An ADA3 K→R acetylation-site mutant showed increased half-life, consistent with competing acetylation and ubiquitination on shared lysines, establishing an RTK-AKT-p300-ADA3 signaling axis.","method":"Kinase inhibitor treatment (lapatinib), p300 phosphorylation assay, ADA3 stability assays, site-directed mutagenesis (K→R), proteasome inhibitor","journal":"Cell cycle","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological and genetic manipulation of pathway, mutant stability assay, single lab","pmids":["28759294"],"is_preprint":false},{"year":2016,"finding":"ADA3 overexpression in mammary epithelial cells and ER+ breast cancer cells enhanced cell proliferation associated with increased cyclin B, c-MYC, SKP2, and early response gene mRNA (c-FOS, EGR1, c-MYC), and decreased p27, establishing that ADA3-driven c-MYC expression mediates its proliferative role.","method":"Ectopic overexpression, RT-PCR, Western blotting, cell proliferation assays","journal":"Breast cancer research","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — overexpression with multiple molecular readouts, consistent with prior KO data, single lab","pmids":["27852327"],"is_preprint":false}],"current_model":"TADA3/ADA3 is a conserved non-enzymatic scaffold subunit of GCN5/PCAF-containing histone acetyltransferase complexes (including SAGA and PCAF/ATAC), where it forms a trimeric core with ADA2 and GCN5 that is necessary and sufficient for nucleosomal HAT activity and lysine specificity; in mammalian cells it is itself dynamically acetylated (by GCN5, PCAF, and p300) and deacetylated (by SIRT1) in a cell cycle-dependent manner—acetylation being required for its role in global histone acetylation and cell proliferation—and it functions as a direct coactivator for p53 (stabilizing p53 by promoting p300-mediated acetylation after DNA damage), nuclear hormone receptors (ERα/β, RARα, RXRα, via LxxLL motifs), and β-catenin; it also localizes to centromeres via direct interaction with CENP-B to regulate chromosome segregation, is required for PCAF/ADA3-PACS2-dependent Bid processing in the granzyme B apoptosis pathway, and is targeted for proteasomal degradation by high-risk HPV E6 through E6AP-mediated ubiquitination potentiated by prior SUMOylation, thereby inactivating multiple ADA3-dependent transcriptional and tumor-suppressive pathways."},"narrative":{"mechanistic_narrative":"TADA3/ADA3 is an evolutionarily conserved, non-enzymatic scaffold subunit of GCN5/PCAF-containing histone acetyltransferase (HAT) complexes that links transcriptional activators to chromatin acetylation and is required for cell proliferation, genome stability, and chromosome segregation [PMID:7862114, PMID:11773077, PMID:22736770]. In yeast it was first defined genetically as a member of the ADA pathway acting together with ADA2 at activator-regulated promoters [PMID:8413201, PMID:8262068], and reconstitution established that ADA2, ADA3, and GCN5 form a heterotrimeric catalytic core—with ADA2 as the linchpin—that is necessary and sufficient for nucleosomal HAT activity and expanded lysine specificity, ADA3 specifically facilitating nucleosomal acetylation [PMID:7862114, PMID:11773077]. Within these complexes ADA3 serves as a coactivator that bridges sequence-specific factors to acetyltransferase activity: it directly binds nuclear hormone receptors ERα/β and RARα through its LxxLL motifs in a hormone-dependent manner, occupies native target promoters, and is required for receptor-driven gene expression and estrogen-dependent proliferation [PMID:15496419, PMID:18089809, PMID:20413580]; it potentiates β-catenin/Wnt target gene activation by promoting β-catenin acetylation [PMID:18059173]; and it acts as a direct p53 coactivator, binding p53 (an interaction enhanced by DNA-damage-induced p53 phosphorylation) and promoting p300/CBP-mediated p53 acetylation to stabilize p53 and induce target genes and senescence [PMID:11707411, PMID:17272277, PMID:17452980]. ADA3 is itself acetylated in a cell-cycle-dependent manner by GCN5, PCAF, and p300 and deacetylated by SIRT1, and this acetylation—regulated by an RTK–AKT–p300 axis that also controls ADA3 stability—is required for global histone acetylation and proliferation [PMID:27402865, PMID:28759294]. Beyond transcription, ADA3 localizes to centromeres via direct interaction with CENP-B to control CENP-B loading and chromosome segregation [PMID:26429915], is required for DNA repair and genomic stability [PMID:23095635], and acts with PCAF upstream of PACS2 in granzyme B-mediated Bid processing during apoptosis [PMID:24464226]. High-risk HPV E6 selectively binds ADA3 and targets it for E6AP-mediated, SUMOylation-potentiated proteasomal degradation, thereby inactivating its p53- and p14ARF-dependent tumor-suppressive functions independently of direct p53 degradation [PMID:12138191, PMID:18256148, PMID:24795430].","teleology":[{"year":1993,"claim":"Established ADA3/NGG1 as a genetic component of the activator-response and glucose-repression machinery, placing it functionally alongside ADA2 rather than as an independent factor.","evidence":"Genetic epistasis, double-mutant analysis, in vitro transcription and reporter assays in yeast","pmids":["8413201","8262068"],"confidence":"Medium","gaps":["No biochemical mechanism or physical complex defined","Molecular activity of ADA3 itself unknown"]},{"year":1995,"claim":"Defined the physical basis of the ADA pathway by reconstituting an ADA2-ADA3-GCN5 heterotrimer and mapping ADA3 domains, answering how the genetic partners assemble into a complex.","evidence":"In vitro reconstitution and domain-deletion mapping with in vivo activation assays","pmids":["7862114"],"confidence":"High","gaps":["Catalytic consequence of trimer assembly not yet tested on nucleosomes","Role of N- vs C-terminal domains in activation only inferred"]},{"year":1997,"claim":"Showed ADA3 and ADA2 are mutually stabilizing, near-stoichiometric partners residing in multiple higher-order complexes and contacting TBP, refining the architecture of native ADA/GCN5 complexes.","evidence":"Reciprocal co-IP with quantification, ion-exchange and gel-filtration chromatography in yeast extracts","pmids":["9038164","9154821"],"confidence":"High","gaps":["Functional roles of distinct complex sizes not resolved","ADA1/ADA5 functional class distinction left mechanistically open"]},{"year":2001,"claim":"Demonstrated the ADA2-ADA3-GCN5 core is necessary and sufficient for nucleosomal HAT activity and lysine specificity, assigning ADA3 a specific role in nucleosomal acetylation and expanded substrate range.","evidence":"In vitro reconstituted HAT assays on nucleosome substrates and yeast extract assays","pmids":["11773077"],"confidence":"High","gaps":["Structural basis of ADA3-dependent specificity not determined","Whether human core behaves identically not yet tested at this stage"]},{"year":2001,"claim":"Extended ADA3 function to a human tumor-suppressor pathway by showing it binds p53 (enhanced after DNA damage) and is required for full p53 transcriptional activity and apoptosis.","evidence":"Yeast p53 dissociator assay, co-IP in human cells, transcription and apoptosis assays","pmids":["11707411"],"confidence":"High","gaps":["Acetylation-based mechanism of p53 activation not yet defined","Which HAT complex mediates the effect not specified"]},{"year":2002,"claim":"Identified ADA3 as a selective high-risk HPV E6 target whose degradation inactivates p53 independently of p53 degradation, defining a distinct viral oncogenic mechanism.","evidence":"Co-IP, degradation assays with E6 mutants, transcriptional and cell-cycle assays","pmids":["12138191"],"confidence":"High","gaps":["Ubiquitin ligase mediating degradation not yet identified","Whether other ADA3 functions are also disrupted not addressed"]},{"year":2002,"claim":"Established ADA3 as a nuclear-receptor coactivator by showing direct RXRα binding and promoter occupancy, while the mouse TFTC study showed nuclear-receptor contact can occur through other subunits, framing how receptor coupling is achieved.","evidence":"In vitro binding, co-IP, ChIP at native p21 promoter; TFTC complex co-IP with ERα","pmids":["12235159","12034840"],"confidence":"Medium","gaps":["Direct vs complex-mediated receptor contact appeared species/context dependent","LxxLL-motif usage not yet functionally tested"]},{"year":2004,"claim":"Confirmed ADA3 as a direct ERα/ERβ coactivator required for endogenous estrogen target gene expression, linking it to estrogen-responsive transcription.","evidence":"Direct binding, ChIP at native pS2 promoter, RNAi knockdown, RT-PCR of multiple targets","pmids":["15496419"],"confidence":"High","gaps":["HAT recruitment role not yet demonstrated","Contribution to proliferation not yet shown"]},{"year":2007,"claim":"Defined the molecular mechanism of ADA3-mediated p53 activation—promotion of p300/CBP-dependent p53 acetylation and stabilization—and separated p53-binding from p300-binding functions required for p14ARF-induced senescence.","evidence":"shRNA/siRNA knockdown, inducible overexpression, p53 acetylation-site and ADA3 N-terminal-domain mutagenesis, co-IP","pmids":["17272277","17452980"],"confidence":"High","gaps":["Stoichiometry of ADA3 in p300 complexes not resolved","Direct enzymatic contribution of ADA3 (non-catalytic) to acetylation not structurally explained"]},{"year":2007,"claim":"Demonstrated ADA3 is required for ligand-dependent recruitment of p300, PCAF, and GCN5 to ER target promoters and for estrogen-dependent breast cancer proliferation, linking its coactivator role to a proliferative oncogenic output.","evidence":"Glycerol gradient cosedimentation, co-IP, ChIP, shRNA knockdown, 2D/3D proliferation assays","pmids":["18089809"],"confidence":"High","gaps":["Whether ADA3 acts as scaffold for HAT delivery vs activator bridging not dissected","Generality beyond ER promoters not tested here"]},{"year":2007,"claim":"Broadened ADA3 coactivator function to Wnt signaling by showing it (with ADA2a) binds β-catenin, occupies the c-Myc enhancer, and promotes β-catenin acetylation and target gene activation.","evidence":"Co-IP with domain mapping, ChIP, RNAi, reporter assays","pmids":["18059173"],"confidence":"Medium","gaps":["Single-lab finding without reciprocal in vivo validation","Whether β-catenin is a direct ADA3-complex acetylation substrate not proven"]},{"year":2007,"claim":"Provided conserved in vivo loss-of-function evidence that the ADA3 ortholog is required for specific GCN5-dependent histone marks (H3K9/K14, H4K12) and for organismal viability and oogenesis.","evidence":"Drosophila genetic mutants, histone-modification immunostaining, genetic interaction analysis","pmids":["17967867"],"confidence":"High","gaps":["Mechanism restricting specificity to particular lysines unexplained","Direct vs indirect effect on H3S10 phosphorylation unresolved"]},{"year":2008,"claim":"Showed ADA3 degradation alone is sufficient for HPV E6-driven immortalization and inactivation of the p14ARF-p53 pathway, and identified ANCO-1/2 as ADA3-interacting regulators that modulate its coactivator activity.","evidence":"E6 mutant immortalization assays; co-IP, domain mapping, co-localization, reporter assays for ANCO proteins","pmids":["18256148","18377363"],"confidence":"Medium","gaps":["ANCO regulatory mechanism single-lab and not validated in vivo","How ADA3 loss bypasses p53 levels mechanistically not fully resolved"]},{"year":2009,"claim":"Identified E6AP as the ubiquitin ligase required for HPV16 E6-induced ADA3 degradation and linked ADA3 restoration to reduced proliferation and increased apoptosis in cervical carcinoma cells.","evidence":"siRNA knockdown of E6/E6AP, protein expression, proliferation and apoptosis assays","pmids":["19194825"],"confidence":"Medium","gaps":["Direct ubiquitination of ADA3 by E6AP not biochemically reconstituted here","Single-lab phenotypic readouts"]},{"year":2010,"claim":"Established the direct, LxxLL-motif-dependent mechanism by which ADA3 engages RARα, confirmed by reciprocal mutagenesis of both the motifs and the receptor coactivator pocket.","evidence":"Co-IP, LxxLL and coactivator-pocket mutagenesis, ChIP at native promoter, siRNA, structural modeling","pmids":["20413580"],"confidence":"High","gaps":["Whether LxxLL usage is identical across all receptors not fully generalized","Crystallographic structure of the interaction not obtained"]},{"year":2012,"claim":"Defined the essential cellular requirement for ADA3 in mammals: embryonic lethality, proliferation and cell-cycle defects via c-Myc/p27 regulation, mitotic defects, global histone acetylation changes, and a requirement for DNA repair and genomic stability.","evidence":"Germline and conditional knockout mice, MEF deletion with human ADA3 rescue, cell-cycle, microarray, histone and DNA-damage marker analyses, cytogenetics, comet assay","pmids":["22736770","23095635"],"confidence":"High","gaps":["Direct vs indirect contribution to specific repair pathways not dissected","Link between histone acetylation defect and repair phenotype not mechanistically resolved"]},{"year":2013,"claim":"Expanded the ADA3 interactome to AATF and the phosphatase regulatory subunits PPP1R7 and PPP2R5D through an ADA2-independent N-terminal region, hinting at links to apoptosis regulation and phosphatase activity.","evidence":"Yeast two-hybrid screen, co-IP, fluorescence microscopy, reporter assays","pmids":["23167988"],"confidence":"Medium","gaps":["Functional consequences of phosphatase-subunit binding untested","Single-lab interactions without reciprocal in vivo validation"]},{"year":2014,"claim":"Placed ADA3 (with PCAF) upstream of PACS2 in the granzyme B apoptosis pathway controlling Bid cleavage, and showed HPV E6-driven ADA3 turnover is potentiated by prior SUMOylation, ordering the degradation mechanism.","evidence":"shRNA/siRNA screens, cytochrome c and Bid cleavage assays, PACS2 epistasis; ubiquitination/SUMOylation assays with Ubc9 depletion","pmids":["24464226","24795430"],"confidence":"High","gaps":["How ADA3/PCAF transcriptionally controls PACS2 not detailed","SUMOylation sites and ubiquitin-SUMO crosstalk single-lab"]},{"year":2015,"claim":"Revealed a non-transcriptional centromeric role: ADA3 binds alpha-satellite DNA and directly interacts with CENP-B via its N-terminus to promote CENP-B loading and support proliferation through chromosome segregation control.","evidence":"Proximity ligation, immunofluorescence, deletion mapping, ChIP on alpha-satellite DNA, CENP-B loading and proliferation rescue with binding-deficient mutant","pmids":["26429915"],"confidence":"High","gaps":["Whether HAT activity is involved at centromeres not addressed","Relationship to the mitotic defects seen in ADA3-null MEFs not directly linked"]},{"year":2016,"claim":"Established that ADA3 is itself regulated by cell-cycle-dependent acetylation (by GCN5, PCAF, p300; reversed by SIRT1) that is functionally required for global histone acetylation and proliferation, and that ADA3-driven c-MYC underlies its proliferative role.","evidence":"Mass spectrometry, site-directed mutagenesis, HAT assays, rescue of ADA3-null MEFs with acetylation-defective mutants; overexpression with molecular readouts","pmids":["27402865","27852327"],"confidence":"High","gaps":["How acetylation alters ADA3 function at the structural level unknown","Interplay of individual acetylation sites not fully dissected"]},{"year":2017,"claim":"Connected upstream growth-factor signaling to ADA3 regulation, defining an RTK/EGFR-HER2–AKT–p300 axis that acetylates and stabilizes ADA3, with acetylation competing against ubiquitination on shared lysines.","evidence":"Lapatinib treatment, p300 phosphorylation and ADA3 stability assays, K→R mutagenesis, proteasome inhibition","pmids":["28759294"],"confidence":"Medium","gaps":["Direct shared-lysine competition not structurally proven","Single-lab pharmacological pathway dissection"]},{"year":null,"claim":"How ADA3 mechanistically integrates its distinct functions—HAT scaffolding, coactivator bridging, centromeric CENP-B loading, and DNA repair—and whether a high-resolution structure explains its non-catalytic specificity and acetylation-dependent switching remains unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No high-resolution structure of human ADA2-ADA3-GCN5 core","Unified model linking transcriptional and centromeric/repair roles absent","Direct substrate scope of ADA3-containing complexes in vivo incompletely mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[7,11,14,15,20]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[6,27]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[2,6,14]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[26]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[16,17]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[16,26]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[9,11,14]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[6,11,14,20]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[6,16,27]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[21,26,29]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[22]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[7,24]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[8,18,19,25]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[15,28]}],"complexes":["SAGA/ADA HAT complex","PCAF complex","TFTC","ADA2-ADA3-GCN5 core"],"partners":["GCN5","ADA2/TADA2A","P300","PCAF","P53","ESR1","RARA","CENP-B"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O75528","full_name":"Transcriptional adapter 3","aliases":["ADA3 homolog","hADA3","STAF54","Transcriptional adapter 3-like","ADA3-like protein"],"length_aa":432,"mass_kda":48.9,"function":"Functions as a component of the PCAF complex. The PCAF complex is capable of efficiently acetylating histones in a nucleosomal context. The PCAF complex could be considered as the human version of the yeast SAGA complex. Also known as a coactivator for p53/TP53-dependent transcriptional activation. Component of the ATAC complex, a complex with histone acetyltransferase activity on histones H3 and H4","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/O75528/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TADA3","classification":"Not Classified","n_dependent_lines":451,"n_total_lines":1208,"dependency_fraction":0.37334437086092714},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"TAF12","stoichiometry":10.0},{"gene":"TRRAP","stoichiometry":10.0},{"gene":"ACTB","stoichiometry":0.2},{"gene":"ENY2","stoichiometry":0.2},{"gene":"SF3B3","stoichiometry":0.2},{"gene":"SF3B5","stoichiometry":0.2},{"gene":"TBP","stoichiometry":0.2},{"gene":"USP22","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/TADA3","total_profiled":1310},"omim":[{"mim_id":"617501","title":"LYSINE ACETYLTRANSFERASE 14; KAT14","url":"https://www.omim.org/entry/617501"},{"mim_id":"613373","title":"YEATS DOMAIN-CONTAINING PROTEIN 2; YEATS2","url":"https://www.omim.org/entry/613373"},{"mim_id":"602945","title":"TRANSCRIPTIONAL ADAPTOR 3; TADA3","url":"https://www.omim.org/entry/602945"},{"mim_id":"602303","title":"LYSINE ACETYLTRANSFERASE 2B; KAT2B","url":"https://www.omim.org/entry/602303"},{"mim_id":"602301","title":"LYSINE ACETYLTRANSFERASE 2A; KAT2A","url":"https://www.omim.org/entry/602301"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TADA3"},"hgnc":{"alias_symbol":["FLJ20221","FLJ21329","ADA3","hADA3","NGG1"],"prev_symbol":["TADA3L"]},"alphafold":{"accession":"O75528","domains":[{"cath_id":"-","chopping":"18-75_342-428","consensus_level":"medium","plddt":92.9828,"start":18,"end":428}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O75528","model_url":"https://alphafold.ebi.ac.uk/files/AF-O75528-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O75528-F1-predicted_aligned_error_v6.png","plddt_mean":75.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TADA3","jax_strain_url":"https://www.jax.org/strain/search?query=TADA3"},"sequence":{"accession":"O75528","fasta_url":"https://rest.uniprot.org/uniprotkb/O75528.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O75528/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O75528"}},"corpus_meta":[{"pmid":"11773077","id":"PMC_11773077","title":"Role of the Ada2 and Ada3 transcriptional coactivators in histone acetylation.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11773077","citation_count":190,"is_preprint":false},{"pmid":"7862114","id":"PMC_7862114","title":"ADA3, a putative transcriptional adaptor, consists of two separable domains and interacts with ADA2 and GCN5 in a trimeric complex.","date":"1995","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7862114","citation_count":158,"is_preprint":false},{"pmid":"12138191","id":"PMC_12138191","title":"Human papillomavirus oncoprotein E6 inactivates the transcriptional coactivator human ADA3.","date":"2002","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12138191","citation_count":116,"is_preprint":false},{"pmid":"9038164","id":"PMC_9038164","title":"Identification of native complexes containing the yeast coactivator/repressor proteins NGG1/ADA3 and ADA2.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9038164","citation_count":105,"is_preprint":false},{"pmid":"8413201","id":"PMC_8413201","title":"ADA3: a gene, identified by resistance to GAL4-VP16, with properties similar to and different from those of ADA2.","date":"1993","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8413201","citation_count":102,"is_preprint":false},{"pmid":"9154821","id":"PMC_9154821","title":"ADA1, a novel component of the ADA/GCN5 complex, has broader effects than GCN5, ADA2, or ADA3.","date":"1997","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9154821","citation_count":93,"is_preprint":false},{"pmid":"11707411","id":"PMC_11707411","title":"hADA3 is required for p53 activity.","date":"2001","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/11707411","citation_count":66,"is_preprint":false},{"pmid":"12235159","id":"PMC_12235159","title":"Human papilloma virus 16 E6 oncoprotein inhibits retinoic X receptor-mediated transactivation by targeting human ADA3 coactivator.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12235159","citation_count":53,"is_preprint":false},{"pmid":"8262068","id":"PMC_8262068","title":"Characterization of NGG1, a novel yeast gene required for glucose repression of GAL4p-regulated transcription.","date":"1993","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/8262068","citation_count":47,"is_preprint":false},{"pmid":"17272277","id":"PMC_17272277","title":"An essential role of human Ada3 in p53 acetylation.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17272277","citation_count":40,"is_preprint":false},{"pmid":"32890768","id":"PMC_32890768","title":"The Ada2/Ada3/Gcn5/Sgf29 histone acetyltransferase module.","date":"2020","source":"Biochimica et biophysica acta. Gene regulatory mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/32890768","citation_count":36,"is_preprint":false},{"pmid":"15496419","id":"PMC_15496419","title":"Human ADA3 binds to estrogen receptor (ER) and functions as a coactivator for ER-mediated transactivation.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15496419","citation_count":31,"is_preprint":false},{"pmid":"8621592","id":"PMC_8621592","title":"Structure/functional properties of the yeast dual regulator protein NGG1 that are required for glucose repression.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8621592","citation_count":30,"is_preprint":false},{"pmid":"17452980","id":"PMC_17452980","title":"hAda3 regulates p14ARF-induced p53 acetylation and senescence.","date":"2007","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/17452980","citation_count":29,"is_preprint":false},{"pmid":"17309836","id":"PMC_17309836","title":"Expression and purification of recombinant yeast Ada2/Ada3/Gcn5 and Piccolo NuA4 histone acetyltransferase complexes.","date":"2007","source":"Methods (San Diego, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/17309836","citation_count":28,"is_preprint":false},{"pmid":"22736770","id":"PMC_22736770","title":"Mammalian alteration/deficiency in activation 3 (Ada3) is essential for embryonic development and cell cycle progression.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22736770","citation_count":26,"is_preprint":false},{"pmid":"18089809","id":"PMC_18089809","title":"Ada3 requirement for HAT recruitment to estrogen receptors and estrogen-dependent breast cancer cell proliferation.","date":"2007","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18089809","citation_count":25,"is_preprint":false},{"pmid":"18256148","id":"PMC_18256148","title":"hAda3 degradation by papillomavirus type 16 E6 correlates with abrogation of the p14ARF-p53 pathway and efficient immortalization of human mammary epithelial cells.","date":"2008","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/18256148","citation_count":20,"is_preprint":false},{"pmid":"18377363","id":"PMC_18377363","title":"Ankyrin repeats-containing cofactors interact with ADA3 and modulate its co-activator function.","date":"2008","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/18377363","citation_count":20,"is_preprint":false},{"pmid":"17967867","id":"PMC_17967867","title":"Transcriptional adaptor ADA3 of Drosophila melanogaster is required for histone modification, position effect variegation, and transcription.","date":"2007","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17967867","citation_count":20,"is_preprint":false},{"pmid":"29670108","id":"PMC_29670108","title":"Down-regulation of a pro-apoptotic pathway regulated by PCAF/ADA3 in early stage gastric cancer.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29670108","citation_count":19,"is_preprint":false},{"pmid":"23095635","id":"PMC_23095635","title":"Alteration/deficiency in activation-3 (Ada3) plays a critical role in maintaining genomic stability.","date":"2012","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/23095635","citation_count":18,"is_preprint":false},{"pmid":"24795430","id":"PMC_24795430","title":"High-risk HPV16E6 stimulates hADA3 degradation by enhancing its SUMOylation.","date":"2014","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/24795430","citation_count":18,"is_preprint":false},{"pmid":"28759294","id":"PMC_28759294","title":"Epidermal Growth Factor Receptor activation promotes ADA3 acetylation through the AKT-p300 pathway.","date":"2017","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/28759294","citation_count":15,"is_preprint":false},{"pmid":"27402865","id":"PMC_27402865","title":"Acetylation of Mammalian ADA3 Is Required for Its Functional Roles in Histone Acetylation and Cell Proliferation.","date":"2016","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/27402865","citation_count":15,"is_preprint":false},{"pmid":"18059173","id":"PMC_18059173","title":"hADA2a and hADA3 are required for acetylation, transcriptional activity and proliferative effects of beta-catenin.","date":"2007","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/18059173","citation_count":14,"is_preprint":false},{"pmid":"26429915","id":"PMC_26429915","title":"Alteration/Deficiency in Activation 3 (ADA3) Protein, a Cell Cycle Regulator, Associates with the Centromere through CENP-B and Regulates Chromosome Segregation.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26429915","citation_count":13,"is_preprint":false},{"pmid":"24464226","id":"PMC_24464226","title":"A functional genomics screen identifies PCAF and ADA3 as regulators of human granzyme B-mediated apoptosis and Bid cleavage.","date":"2014","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/24464226","citation_count":12,"is_preprint":false},{"pmid":"27852327","id":"PMC_27852327","title":"ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC.","date":"2016","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/27852327","citation_count":11,"is_preprint":false},{"pmid":"12034840","id":"PMC_12034840","title":"ADA3-containing complexes associate with estrogen receptor alpha.","date":"2002","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/12034840","citation_count":11,"is_preprint":false},{"pmid":"23167988","id":"PMC_23167988","title":"Identification of transcriptional and phosphatase regulators as interaction partners of human ADA3, a component of histone acetyltransferase complexes.","date":"2013","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/23167988","citation_count":10,"is_preprint":false},{"pmid":"20413580","id":"PMC_20413580","title":"Human ADA3 regulates RARalpha transcriptional activity through direct contact between LxxLL motifs and the receptor coactivator pocket.","date":"2010","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/20413580","citation_count":9,"is_preprint":false},{"pmid":"29110536","id":"PMC_29110536","title":"Histone acetyltransferase encoded by NGG1 is required for morphological conversion and virulence of Candida albicans.","date":"2017","source":"Future microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/29110536","citation_count":9,"is_preprint":false},{"pmid":"19194825","id":"PMC_19194825","title":"HPV16 E6-induced and E6AP-dependent inhibition of the transcriptional coactivator hADA3 in human cervical carcinoma cells.","date":"2009","source":"Cancer investigation","url":"https://pubmed.ncbi.nlm.nih.gov/19194825","citation_count":9,"is_preprint":false},{"pmid":"36160216","id":"PMC_36160216","title":"Deletion of NGG1 in a recombinant Saccharomyces cerevisiae improved xylose utilization and affected transcription of genes related to amino acid metabolism.","date":"2022","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/36160216","citation_count":6,"is_preprint":false},{"pmid":"36715154","id":"PMC_36715154","title":"The Gcn5-Ada2-Ada3 histone acetyltransferase module has divergent roles in pathogenesis of Candida glabrata.","date":"2023","source":"Medical mycology","url":"https://pubmed.ncbi.nlm.nih.gov/36715154","citation_count":5,"is_preprint":false},{"pmid":"37052485","id":"PMC_37052485","title":"Ada2 and Ada3 Regulate Hyphal Growth, Asexual Development, and Pathogenicity in Beauveria bassiana by Maintaining Gcn5 Acetyltransferase Activity.","date":"2023","source":"Microbiology spectrum","url":"https://pubmed.ncbi.nlm.nih.gov/37052485","citation_count":4,"is_preprint":false},{"pmid":"27605378","id":"PMC_27605378","title":"Tale of a multifaceted co-activator, hADA3: from embryogenesis to cancer and beyond.","date":"2016","source":"Open biology","url":"https://pubmed.ncbi.nlm.nih.gov/27605378","citation_count":4,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":20212,"output_tokens":7582,"usd":0.087183,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16942,"output_tokens":6960,"usd":0.129355,"stage2_stop_reason":"end_turn"},"total_usd":0.216538,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"ADA3 (NGG1) was identified as a yeast gene whose mutations prevent toxicity of GAL4-VP16; double disruption of ada2 and ada3 showed no additive growth defect, placing ADA3 in the same pathway as ADA2. Selection of transcription initiation sites in vitro was altered in ada3 mutants, suggesting a role in the response to acidic activators.\",\n      \"method\": \"Genetic epistasis (double mutant analysis), in vitro transcription initiation assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis with double mutant and in vitro transcription assay, single lab\",\n      \"pmids\": [\"8413201\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"NGG1 (ADA3) was identified as required for glucose repression of GAL4p-activated genes; its activity was GAL4-dependent and promoter analysis showed a correlation between the number of GAL4p binding sites and NGG1p activity, establishing a functional role in repression at GAL4-regulated promoters.\",\n      \"method\": \"Genetic screen, promoter deletion analysis, reporter assays in yeast\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and reporter assays, single lab, two complementary approaches\",\n      \"pmids\": [\"8262068\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"ADA2, ADA3, and GCN5 form a heterotrimeric complex in vitro, with ADA2 serving as the linchpin holding ADA3 and GCN5 together. The C-terminal domain of ADA3 is sufficient for complex formation, while the N-terminal domain mediates interaction between activation domains and the ADA complex.\",\n      \"method\": \"In vitro reconstitution, domain deletion analysis, in vivo activation assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution of trimeric complex plus domain mapping, replicated in subsequent studies\",\n      \"pmids\": [\"7862114\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"NGG1p/ADA3p requires residues 274-373 (including an amphipathic alpha-helix rich in Phe residues) for glucose repression. Single and double disruptions of ngg1 and ada2 had comparable effects on glucose repression, confirming they act in the same complex. An ADA2p-interaction site was mapped to residues 308-373 of NGG1p.\",\n      \"method\": \"Deletion mutagenesis, genetic epistasis, in vivo reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — deletion mutagenesis with functional readout plus epistasis, single lab\",\n      \"pmids\": [\"8621592\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"NGG1p/ADA3p and ADA2p are co-immunoprecipitated from yeast whole-cell extracts (less than 2% of ADA2p was not associated with NGG1p), and each protein's stability depends on the other. NGG1p-containing complexes of approximately 200 kDa, 900 kDa, and >2 MDa were resolved, and TBP co-immunoprecipitated with NGG1p in a manner requiring NGG1p residues 274-307.\",\n      \"method\": \"Co-immunoprecipitation, ion-exchange chromatography, gel filtration\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP with quantification, multiple chromatographic methods, replicated domain requirement\",\n      \"pmids\": [\"9038164\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"ADA1 interacts with ADA3 and other ADA complex members as shown by partial purification and immunoprecipitation, and the ADA/GCN5 complex has an estimated molecular mass of approximately 2 MDa. ADA1 and ADA5 mutations produce more severe defects than ada2/ada3/gcn5 mutations, suggesting two functional classes within the complex.\",\n      \"method\": \"Partial complex purification, co-immunoprecipitation, genetic phenotypic analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus genetic epistasis, single lab\",\n      \"pmids\": [\"9154821\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Yeast Ada2, Ada3, and Gcn5 form the catalytic core of ADA and SAGA HAT complexes; this trimeric core is necessary and sufficient for nucleosomal HAT activity and lysine specificity in vitro. Ada3 is necessary for Gcn5-dependent nucleosomal HAT activity in yeast extracts; Ada2 potentiates Gcn5 catalytic activity, while Ada3 facilitates nucleosomal acetylation and expanded lysine specificity.\",\n      \"method\": \"In vitro reconstitution of HAT activity with nucleosome substrates, yeast extract HAT assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted catalytic core in vitro with nucleosome substrate, multiple functional readouts\",\n      \"pmids\": [\"11773077\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"hADA3 physically interacts with p53 in human cells; this interaction is enhanced after DNA damage due to phosphorylation of the p53 N-terminus. hADA3 is required for full p53 transcriptional activity and p53-mediated apoptosis, and was identified as a component of histone acetyltransferase complexes.\",\n      \"method\": \"Yeast p53 dissociator assay, co-immunoprecipitation in human cells, functional transcription and apoptosis assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP, genetic interaction screen, functional transcription and apoptosis assays in human cells\",\n      \"pmids\": [\"11707411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"hADA3 binds selectively to high-risk HPV E6 proteins (not low-risk) and is targeted for E6-induced degradation. HPV E6 mutants that cannot degrade p53 but can interact with hADA3 abrogate p53-mediated transactivation and G1 arrest after DNA damage, revealing a p53-degradation-independent mechanism of p53 inactivation via hADA3.\",\n      \"method\": \"Co-immunoprecipitation, protein degradation assays, transcriptional reporter assays, cell cycle analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP, degradation assays with E6 mutants, functional p53 assays, multiple orthogonal approaches\",\n      \"pmids\": [\"12138191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"hADA3 directly binds RXRalpha in vitro and in vivo, and is part of activator complexes bound to native RXR response elements within the p21 promoter as shown by chromatin immunoprecipitation. hADA3 enhances RXRalpha-mediated transactivation of retinoid target genes, and HPV E6 inhibits this RXRalpha-mediated transactivation by targeting hADA3.\",\n      \"method\": \"In vitro binding assay, co-immunoprecipitation, chromatin immunoprecipitation, transcriptional reporter assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vitro direct binding, ChIP at native promoter, functional reporter assay, multiple orthogonal methods\",\n      \"pmids\": [\"12235159\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Mouse mADA3-containing TFTC (TBP-free-TAF-containing) complex interacts with ERalpha in a ligand-independent manner; mADA3 itself does not directly interact with nuclear receptors despite containing two LxxLL NR boxes, indicating other complex subunits mediate the interaction.\",\n      \"method\": \"Co-immunoprecipitation, cloning and characterization of mouse ADA3\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP of complex with ER, direct binding test (negative for mADA3 alone), single lab\",\n      \"pmids\": [\"12034840\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"hADA3 directly interacts with ERalpha and ERbeta; hADA3 is a component of activator complexes bound to the native ER response element in the pS2 promoter (shown by ChIP); RNA interference-mediated knockdown of endogenous hADA3 inhibited ER-mediated transactivation and estrogen-induced expression of pS2, cathepsin D, and progesterone receptor.\",\n      \"method\": \"Co-immunoprecipitation, chromatin immunoprecipitation, RNA interference, transcriptional reporter assay, RT-PCR\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct binding, ChIP at native promoter, endogenous knockdown with multiple target gene readouts\",\n      \"pmids\": [\"15496419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"hAda3 stabilizes p53 protein by promoting its acetylation at p300/CBP sites; hAda3-dependent acetylation is required for increased p53 stability and target gene induction. Endogenous hAda3 is essential for DNA damage-induced acetylation and stabilization of p53, placing hAda3 as a component of p300/CBP-containing coactivator complexes that mediate p53 acetylation.\",\n      \"method\": \"shRNA knockdown, inducible overexpression, site-directed mutagenesis of p53 acetylation sites, co-immunoprecipitation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (knockdown, OE, mutagenesis, co-IP), replicated across prior and current lab findings\",\n      \"pmids\": [\"17272277\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"p14ARF-induced senescence requires hAda3; expression of the N-terminal domain of hAda3 (which binds p53 but not p300) blocked p14ARF-induced p53 acetylation and senescence. hAda3 overexpression increased p300-mediated p53 acetylation, and siRNA knockdown decreased p53 acetylation and p21cip1 accumulation in response to p14ARF.\",\n      \"method\": \"Domain expression (N-terminal fragment), siRNA knockdown, HPV16 E6 mutant Y54D selective degradation, p53 acetylation assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — domain dissection identifying separable p53-binding and p300-binding functions, siRNA knockdown, selective E6 mutant validation\",\n      \"pmids\": [\"17452980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Ada3, ERalpha, and three HATs (p300, PCAF, and Gcn5) are present in a complex demonstrated by glycerol gradient cosedimentation and immunoprecipitation. shRNA-mediated knockdown of Ada3 in ER-positive breast cancer cells significantly reduced ligand-dependent recruitment of p300, PCAF, and Gcn5 to the ER-responsive pS2 promoter, and Ada3 is critical for estrogen-dependent proliferation.\",\n      \"method\": \"Glycerol gradient cosedimentation, co-immunoprecipitation, chromatin immunoprecipitation, shRNA knockdown, 2D/3D proliferation assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods; ChIP demonstrates functional requirement for HAT recruitment; shRNA with proliferation phenotype\",\n      \"pmids\": [\"18089809\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"hADA2a and hADA3 physically interact with beta-catenin through its Armadillo repeats 6-12 and C-terminal transactivation domain; both proteins reside with beta-catenin at the c-Myc enhancer. RNAi-mediated reduction of hADA2a and hADA3 results in reduced beta-catenin acetylation, reduced reporter activity, and reduced activation of endogenous Wnt target genes.\",\n      \"method\": \"Co-immunoprecipitation, chromatin immunoprecipitation, RNA interference, transcriptional reporter assays, domain mapping\",\n      \"journal\": \"Cancer biology & therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP with domain mapping, ChIP, and RNAi functional assays, single lab\",\n      \"pmids\": [\"18059173\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Drosophila dADA3 localizes to chromosomes and its levels are significantly reduced in dGcn5 and dAda2a (but not dAda2b) mutant backgrounds. dAda3 mutants show reduced acetylation specifically at histone H3 K9 and K14 (not K18) and H4 K12 (not K5, K8, K16), and reduced H3 S10 phosphorylation also seen in dGcn5 mutants. dADA3 is required for oogenesis and somatic cell viability.\",\n      \"method\": \"Genetic mutant analysis, immunostaining for histone modifications, localization studies, genetic interaction\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic loss-of-function in Drosophila with specific histone modification readouts, ortholog confirmed by functional conservation\",\n      \"pmids\": [\"17967867\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ANCO-1 and ANCO-2 interact with ADA3; the interaction occurs between the conserved C-terminal domain of ANCO-1 and the N-terminal transactivation domain of ADA3. ANCO-1 colocalizes with ADA3, ADA2alpha/beta, and PCAF at nuclear dots in vivo. ANCO-1 and ANCO-2 repress ADA3-mediated transcriptional co-activation on nuclear receptors, while ANCO-1 stimulates p53-mediated transactivation.\",\n      \"method\": \"Co-immunoprecipitation, domain mapping, immunofluorescence co-localization, transcriptional reporter assay\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — co-IP with domain mapping and functional reporter assay, single lab\",\n      \"pmids\": [\"18377363\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"HPV16 E6 mutants that degrade hAda3 but not p53 abrogate p14ARF-induced growth arrest and efficiently immortalize mammary epithelial cells despite normal p53 levels, establishing that hAda3 degradation (not only p53 degradation) is sufficient for inactivation of the p14ARF-p53 pathway.\",\n      \"method\": \"HPV16 E6 mutant analysis, protein degradation assays, cell proliferation/immortalization assays\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional E6 mutant panel with clear mechanistic separation of hAda3 vs. p53 degradation, single lab\",\n      \"pmids\": [\"18256148\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"HPV16 E6-induced degradation of hADA3 in cervical carcinoma cells is E6AP-dependent; siRNA knockdown of E6 or E6AP increased hADA3 protein levels, decreased cellular proliferation, and increased apoptotic rate.\",\n      \"method\": \"siRNA knockdown, protein expression analysis, proliferation and apoptosis assays\",\n      \"journal\": \"Cancer investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA with multiple phenotypic readouts, single lab\",\n      \"pmids\": [\"19194825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"hADA3 interacts directly with RARalpha in a hormone-dependent manner through its LxxLL motifs engaging the receptor coactivator pocket; loss- and gain-of-function mutations in LxxLL motifs and the receptor coactivator pocket confirmed this mechanism. hADA3 associates with RARalpha target gene promoters in a hormone-dependent manner, and ADA3 knockdown impairs RARbeta2 expression.\",\n      \"method\": \"Co-immunoprecipitation, site-directed mutagenesis (LxxLL motifs and receptor coactivator pocket), chromatin immunoprecipitation, siRNA knockdown, structural modeling\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct binding confirmed by mutagenesis of both partners (LxxLL and coactivator pocket), ChIP at native promoter, functional gene expression readout\",\n      \"pmids\": [\"20413580\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Germline deletion of Ada3 in mouse is embryonic lethal; conditional deletion in MEFs causes severe proliferation defect, G1-to-S delay due to accumulation of CDK inhibitor p27 (an indirect effect of Ada3-regulated c-Myc transcription), mitotic defects, and drastic changes in global histone acetylation.\",\n      \"method\": \"Germline and conditional knockout mouse, adenovirus-Cre deletion of Ada3(FL/FL) MEFs, rescue by human Ada3 expression, cell cycle analysis, microarray, histone modification analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean conditional KO with multiple orthogonal readouts (cell cycle, histone acetylation, gene expression), genetic rescue, mouse embryo lethality\",\n      \"pmids\": [\"22736770\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Ada3 deletion leads to increased markers of DNA damage (pATM, gammaH2AX, p53BP1, pRAD51) in untreated cells and a significant delay in disappearance of DNA damage foci after ionizing radiation. Ada3-null cells show enhanced chromosomal aberrations (breaks, fragments, deletions, translocations), establishing Ada3 as required for the DNA repair process and genomic stability.\",\n      \"method\": \"Conditional Ada3 knockout (adenovirus-Cre in Ada3(fl/fl) MEFs), immunofluorescence for DNA damage markers, chromosomal aberration analysis, comet assay\",\n      \"journal\": \"Cell cycle\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean conditional KO with multiple DNA damage marker readouts and cytogenetic analysis, same genetic system replicated from prior study\",\n      \"pmids\": [\"23095635\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Three novel hADA3-interacting partners were identified by yeast two-hybrid: AATF (apoptosis-antagonizing transcription factor), PPP1R7 (PP1 regulatory subunit), and PPP2R5D (PP2A regulatory subunit). The C-terminal ADA2-interacting domain of hADA3 was not required for these interactions. Co-localization and co-immunoprecipitation in human cells confirmed the interactions.\",\n      \"method\": \"Yeast two-hybrid screen, co-immunoprecipitation, fluorescence microscopy, transcriptional reporter assay\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — yeast two-hybrid identified, validated by co-IP and co-localization, functional reporter assay, single lab\",\n      \"pmids\": [\"23167988\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PCAF and ADA3 regulate granzyme B-mediated Bid cleavage upstream of mitochondrial membrane permeabilization; knockdown of PCAF or ADA3 reduced PACS2 expression, and PACS2 knockdown phenocopied the PCAF/ADA3 knockdown effect on Bid processing and cytochrome c release, placing ADA3-PCAF upstream of PACS2 in the granzyme B apoptosis pathway.\",\n      \"method\": \"shRNA screen, siRNA knockdown, cytochrome c release assay, Bid cleavage assay, genetic epistasis by PACS2 knockdown\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — functional genetic screen validated by siRNA, epistasis established by phenocopy, multiple orthogonal apoptosis readouts\",\n      \"pmids\": [\"24464226\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"HPV16 E6 targets hADA3 for ubiquitin-mediated degradation via E6AP ubiquitin ligase; hADA3 undergoes SUMOylation that is accelerated in the presence of HPV16E6 and makes hADA3 unstable. Depletion of Ubc9 (SUMO E2 enzyme) prevented rapid hADA3 degradation, establishing that SUMOylation precedes and promotes E6-mediated ubiquitination of hADA3.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, SUMOylation assay, Ubc9 depletion, protein stability assays\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple biochemical assays (ubiquitination, SUMOylation, E2 depletion), mechanistic ordering established, single lab\",\n      \"pmids\": [\"24795430\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ADA3 associates with the higher-order repeat region of alpha-satellite DNA on human X chromosome centromeres, and directly interacts with centromere protein CENP-B through its N-terminus (shown by proximity ligation assay, immunofluorescence, and deletional analysis). Knockdown of ADA3 decreased CENP-B loading onto centromeres, and a CENP-B binding-deficient ADA3 mutant failed to rescue cell proliferation in Ada3-deleted MEFs.\",\n      \"method\": \"Proximity ligation assay, immunofluorescence, deletion mutagenesis, ChIP on alpha-satellite DNA, CENP-B loading assay, proliferation rescue assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal localization methods, domain mapping, functional rescue with binding-deficient mutant\",\n      \"pmids\": [\"26429915\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ADA3 is acetylated in a cell cycle-dependent manner by GCN5, PCAF, and p300; SIRT1 is identified as a deacetylase that opposes this acetylation. Mass spectrometry and site-directed mutagenesis identified major acetylation sites. Acetylation-defective ADA3 mutants could interact with HATs but failed to restore global or locus-specific histone acetylation or cell proliferation in Ada3-deleted MEFs, establishing that ADA3 acetylation is functionally required.\",\n      \"method\": \"Mass spectrometry, site-directed mutagenesis, co-immunoprecipitation, HAT activity assays, rescue of Ada3-deleted MEFs\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — MS identification of sites, mutagenesis, functional rescue assay with acetylation-defective mutants, writer/eraser identification\",\n      \"pmids\": [\"27402865\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"AKT activation downstream of EGFR/HER2 promotes phosphorylation of p300, which in turn promotes acetylation of ADA3. Lapatinib-mediated inhibition of HER1/HER2 reduced phospho-AKT, p300 phosphorylation, and ADA3 protein levels in a proteasome-dependent manner. An ADA3 K→R acetylation-site mutant showed increased half-life, consistent with competing acetylation and ubiquitination on shared lysines, establishing an RTK-AKT-p300-ADA3 signaling axis.\",\n      \"method\": \"Kinase inhibitor treatment (lapatinib), p300 phosphorylation assay, ADA3 stability assays, site-directed mutagenesis (K→R), proteasome inhibitor\",\n      \"journal\": \"Cell cycle\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological and genetic manipulation of pathway, mutant stability assay, single lab\",\n      \"pmids\": [\"28759294\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ADA3 overexpression in mammary epithelial cells and ER+ breast cancer cells enhanced cell proliferation associated with increased cyclin B, c-MYC, SKP2, and early response gene mRNA (c-FOS, EGR1, c-MYC), and decreased p27, establishing that ADA3-driven c-MYC expression mediates its proliferative role.\",\n      \"method\": \"Ectopic overexpression, RT-PCR, Western blotting, cell proliferation assays\",\n      \"journal\": \"Breast cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — overexpression with multiple molecular readouts, consistent with prior KO data, single lab\",\n      \"pmids\": [\"27852327\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TADA3/ADA3 is a conserved non-enzymatic scaffold subunit of GCN5/PCAF-containing histone acetyltransferase complexes (including SAGA and PCAF/ATAC), where it forms a trimeric core with ADA2 and GCN5 that is necessary and sufficient for nucleosomal HAT activity and lysine specificity; in mammalian cells it is itself dynamically acetylated (by GCN5, PCAF, and p300) and deacetylated (by SIRT1) in a cell cycle-dependent manner—acetylation being required for its role in global histone acetylation and cell proliferation—and it functions as a direct coactivator for p53 (stabilizing p53 by promoting p300-mediated acetylation after DNA damage), nuclear hormone receptors (ERα/β, RARα, RXRα, via LxxLL motifs), and β-catenin; it also localizes to centromeres via direct interaction with CENP-B to regulate chromosome segregation, is required for PCAF/ADA3-PACS2-dependent Bid processing in the granzyme B apoptosis pathway, and is targeted for proteasomal degradation by high-risk HPV E6 through E6AP-mediated ubiquitination potentiated by prior SUMOylation, thereby inactivating multiple ADA3-dependent transcriptional and tumor-suppressive pathways.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TADA3/ADA3 is an evolutionarily conserved, non-enzymatic scaffold subunit of GCN5/PCAF-containing histone acetyltransferase (HAT) complexes that links transcriptional activators to chromatin acetylation and is required for cell proliferation, genome stability, and chromosome segregation [#2, #6, #21]. In yeast it was first defined genetically as a member of the ADA pathway acting together with ADA2 at activator-regulated promoters [#0, #1], and reconstitution established that ADA2, ADA3, and GCN5 form a heterotrimeric catalytic core\\u2014with ADA2 as the linchpin\\u2014that is necessary and sufficient for nucleosomal HAT activity and expanded lysine specificity, ADA3 specifically facilitating nucleosomal acetylation [#2, #6]. Within these complexes ADA3 serves as a coactivator that bridges sequence-specific factors to acetyltransferase activity: it directly binds nuclear hormone receptors ER\\u03b1/\\u03b2 and RAR\\u03b1 through its LxxLL motifs in a hormone-dependent manner, occupies native target promoters, and is required for receptor-driven gene expression and estrogen-dependent proliferation [#11, #14, #20]; it potentiates \\u03b2-catenin/Wnt target gene activation by promoting \\u03b2-catenin acetylation [#15]; and it acts as a direct p53 coactivator, binding p53 (an interaction enhanced by DNA-damage-induced p53 phosphorylation) and promoting p300/CBP-mediated p53 acetylation to stabilize p53 and induce target genes and senescence [#7, #12, #13]. ADA3 is itself acetylated in a cell-cycle-dependent manner by GCN5, PCAF, and p300 and deacetylated by SIRT1, and this acetylation\\u2014regulated by an RTK\\u2013AKT\\u2013p300 axis that also controls ADA3 stability\\u2014is required for global histone acetylation and proliferation [#27, #28]. Beyond transcription, ADA3 localizes to centromeres via direct interaction with CENP-B to control CENP-B loading and chromosome segregation [#26], is required for DNA repair and genomic stability [#22], and acts with PCAF upstream of PACS2 in granzyme B-mediated Bid processing during apoptosis [#24]. High-risk HPV E6 selectively binds ADA3 and targets it for E6AP-mediated, SUMOylation-potentiated proteasomal degradation, thereby inactivating its p53- and p14ARF-dependent tumor-suppressive functions independently of direct p53 degradation [#8, #18, #25].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Established ADA3/NGG1 as a genetic component of the activator-response and glucose-repression machinery, placing it functionally alongside ADA2 rather than as an independent factor.\",\n      \"evidence\": \"Genetic epistasis, double-mutant analysis, in vitro transcription and reporter assays in yeast\",\n      \"pmids\": [\"8413201\", \"8262068\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No biochemical mechanism or physical complex defined\", \"Molecular activity of ADA3 itself unknown\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Defined the physical basis of the ADA pathway by reconstituting an ADA2-ADA3-GCN5 heterotrimer and mapping ADA3 domains, answering how the genetic partners assemble into a complex.\",\n      \"evidence\": \"In vitro reconstitution and domain-deletion mapping with in vivo activation assays\",\n      \"pmids\": [\"7862114\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Catalytic consequence of trimer assembly not yet tested on nucleosomes\", \"Role of N- vs C-terminal domains in activation only inferred\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Showed ADA3 and ADA2 are mutually stabilizing, near-stoichiometric partners residing in multiple higher-order complexes and contacting TBP, refining the architecture of native ADA/GCN5 complexes.\",\n      \"evidence\": \"Reciprocal co-IP with quantification, ion-exchange and gel-filtration chromatography in yeast extracts\",\n      \"pmids\": [\"9038164\", \"9154821\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional roles of distinct complex sizes not resolved\", \"ADA1/ADA5 functional class distinction left mechanistically open\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrated the ADA2-ADA3-GCN5 core is necessary and sufficient for nucleosomal HAT activity and lysine specificity, assigning ADA3 a specific role in nucleosomal acetylation and expanded substrate range.\",\n      \"evidence\": \"In vitro reconstituted HAT assays on nucleosome substrates and yeast extract assays\",\n      \"pmids\": [\"11773077\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of ADA3-dependent specificity not determined\", \"Whether human core behaves identically not yet tested at this stage\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Extended ADA3 function to a human tumor-suppressor pathway by showing it binds p53 (enhanced after DNA damage) and is required for full p53 transcriptional activity and apoptosis.\",\n      \"evidence\": \"Yeast p53 dissociator assay, co-IP in human cells, transcription and apoptosis assays\",\n      \"pmids\": [\"11707411\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Acetylation-based mechanism of p53 activation not yet defined\", \"Which HAT complex mediates the effect not specified\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identified ADA3 as a selective high-risk HPV E6 target whose degradation inactivates p53 independently of p53 degradation, defining a distinct viral oncogenic mechanism.\",\n      \"evidence\": \"Co-IP, degradation assays with E6 mutants, transcriptional and cell-cycle assays\",\n      \"pmids\": [\"12138191\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ubiquitin ligase mediating degradation not yet identified\", \"Whether other ADA3 functions are also disrupted not addressed\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Established ADA3 as a nuclear-receptor coactivator by showing direct RXR\\u03b1 binding and promoter occupancy, while the mouse TFTC study showed nuclear-receptor contact can occur through other subunits, framing how receptor coupling is achieved.\",\n      \"evidence\": \"In vitro binding, co-IP, ChIP at native p21 promoter; TFTC complex co-IP with ER\\u03b1\",\n      \"pmids\": [\"12235159\", \"12034840\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs complex-mediated receptor contact appeared species/context dependent\", \"LxxLL-motif usage not yet functionally tested\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Confirmed ADA3 as a direct ER\\u03b1/ER\\u03b2 coactivator required for endogenous estrogen target gene expression, linking it to estrogen-responsive transcription.\",\n      \"evidence\": \"Direct binding, ChIP at native pS2 promoter, RNAi knockdown, RT-PCR of multiple targets\",\n      \"pmids\": [\"15496419\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"HAT recruitment role not yet demonstrated\", \"Contribution to proliferation not yet shown\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defined the molecular mechanism of ADA3-mediated p53 activation\\u2014promotion of p300/CBP-dependent p53 acetylation and stabilization\\u2014and separated p53-binding from p300-binding functions required for p14ARF-induced senescence.\",\n      \"evidence\": \"shRNA/siRNA knockdown, inducible overexpression, p53 acetylation-site and ADA3 N-terminal-domain mutagenesis, co-IP\",\n      \"pmids\": [\"17272277\", \"17452980\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of ADA3 in p300 complexes not resolved\", \"Direct enzymatic contribution of ADA3 (non-catalytic) to acetylation not structurally explained\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Demonstrated ADA3 is required for ligand-dependent recruitment of p300, PCAF, and GCN5 to ER target promoters and for estrogen-dependent breast cancer proliferation, linking its coactivator role to a proliferative oncogenic output.\",\n      \"evidence\": \"Glycerol gradient cosedimentation, co-IP, ChIP, shRNA knockdown, 2D/3D proliferation assays\",\n      \"pmids\": [\"18089809\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ADA3 acts as scaffold for HAT delivery vs activator bridging not dissected\", \"Generality beyond ER promoters not tested here\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Broadened ADA3 coactivator function to Wnt signaling by showing it (with ADA2a) binds \\u03b2-catenin, occupies the c-Myc enhancer, and promotes \\u03b2-catenin acetylation and target gene activation.\",\n      \"evidence\": \"Co-IP with domain mapping, ChIP, RNAi, reporter assays\",\n      \"pmids\": [\"18059173\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab finding without reciprocal in vivo validation\", \"Whether \\u03b2-catenin is a direct ADA3-complex acetylation substrate not proven\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Provided conserved in vivo loss-of-function evidence that the ADA3 ortholog is required for specific GCN5-dependent histone marks (H3K9/K14, H4K12) and for organismal viability and oogenesis.\",\n      \"evidence\": \"Drosophila genetic mutants, histone-modification immunostaining, genetic interaction analysis\",\n      \"pmids\": [\"17967867\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism restricting specificity to particular lysines unexplained\", \"Direct vs indirect effect on H3S10 phosphorylation unresolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Showed ADA3 degradation alone is sufficient for HPV E6-driven immortalization and inactivation of the p14ARF-p53 pathway, and identified ANCO-1/2 as ADA3-interacting regulators that modulate its coactivator activity.\",\n      \"evidence\": \"E6 mutant immortalization assays; co-IP, domain mapping, co-localization, reporter assays for ANCO proteins\",\n      \"pmids\": [\"18256148\", \"18377363\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"ANCO regulatory mechanism single-lab and not validated in vivo\", \"How ADA3 loss bypasses p53 levels mechanistically not fully resolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identified E6AP as the ubiquitin ligase required for HPV16 E6-induced ADA3 degradation and linked ADA3 restoration to reduced proliferation and increased apoptosis in cervical carcinoma cells.\",\n      \"evidence\": \"siRNA knockdown of E6/E6AP, protein expression, proliferation and apoptosis assays\",\n      \"pmids\": [\"19194825\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct ubiquitination of ADA3 by E6AP not biochemically reconstituted here\", \"Single-lab phenotypic readouts\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Established the direct, LxxLL-motif-dependent mechanism by which ADA3 engages RAR\\u03b1, confirmed by reciprocal mutagenesis of both the motifs and the receptor coactivator pocket.\",\n      \"evidence\": \"Co-IP, LxxLL and coactivator-pocket mutagenesis, ChIP at native promoter, siRNA, structural modeling\",\n      \"pmids\": [\"20413580\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether LxxLL usage is identical across all receptors not fully generalized\", \"Crystallographic structure of the interaction not obtained\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Defined the essential cellular requirement for ADA3 in mammals: embryonic lethality, proliferation and cell-cycle defects via c-Myc/p27 regulation, mitotic defects, global histone acetylation changes, and a requirement for DNA repair and genomic stability.\",\n      \"evidence\": \"Germline and conditional knockout mice, MEF deletion with human ADA3 rescue, cell-cycle, microarray, histone and DNA-damage marker analyses, cytogenetics, comet assay\",\n      \"pmids\": [\"22736770\", \"23095635\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs indirect contribution to specific repair pathways not dissected\", \"Link between histone acetylation defect and repair phenotype not mechanistically resolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Expanded the ADA3 interactome to AATF and the phosphatase regulatory subunits PPP1R7 and PPP2R5D through an ADA2-independent N-terminal region, hinting at links to apoptosis regulation and phosphatase activity.\",\n      \"evidence\": \"Yeast two-hybrid screen, co-IP, fluorescence microscopy, reporter assays\",\n      \"pmids\": [\"23167988\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequences of phosphatase-subunit binding untested\", \"Single-lab interactions without reciprocal in vivo validation\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Placed ADA3 (with PCAF) upstream of PACS2 in the granzyme B apoptosis pathway controlling Bid cleavage, and showed HPV E6-driven ADA3 turnover is potentiated by prior SUMOylation, ordering the degradation mechanism.\",\n      \"evidence\": \"shRNA/siRNA screens, cytochrome c and Bid cleavage assays, PACS2 epistasis; ubiquitination/SUMOylation assays with Ubc9 depletion\",\n      \"pmids\": [\"24464226\", \"24795430\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ADA3/PCAF transcriptionally controls PACS2 not detailed\", \"SUMOylation sites and ubiquitin-SUMO crosstalk single-lab\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Revealed a non-transcriptional centromeric role: ADA3 binds alpha-satellite DNA and directly interacts with CENP-B via its N-terminus to promote CENP-B loading and support proliferation through chromosome segregation control.\",\n      \"evidence\": \"Proximity ligation, immunofluorescence, deletion mapping, ChIP on alpha-satellite DNA, CENP-B loading and proliferation rescue with binding-deficient mutant\",\n      \"pmids\": [\"26429915\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether HAT activity is involved at centromeres not addressed\", \"Relationship to the mitotic defects seen in ADA3-null MEFs not directly linked\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Established that ADA3 is itself regulated by cell-cycle-dependent acetylation (by GCN5, PCAF, p300; reversed by SIRT1) that is functionally required for global histone acetylation and proliferation, and that ADA3-driven c-MYC underlies its proliferative role.\",\n      \"evidence\": \"Mass spectrometry, site-directed mutagenesis, HAT assays, rescue of ADA3-null MEFs with acetylation-defective mutants; overexpression with molecular readouts\",\n      \"pmids\": [\"27402865\", \"27852327\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How acetylation alters ADA3 function at the structural level unknown\", \"Interplay of individual acetylation sites not fully dissected\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Connected upstream growth-factor signaling to ADA3 regulation, defining an RTK/EGFR-HER2\\u2013AKT\\u2013p300 axis that acetylates and stabilizes ADA3, with acetylation competing against ubiquitination on shared lysines.\",\n      \"evidence\": \"Lapatinib treatment, p300 phosphorylation and ADA3 stability assays, K\\u2192R mutagenesis, proteasome inhibition\",\n      \"pmids\": [\"28759294\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct shared-lysine competition not structurally proven\", \"Single-lab pharmacological pathway dissection\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ADA3 mechanistically integrates its distinct functions\\u2014HAT scaffolding, coactivator bridging, centromeric CENP-B loading, and DNA repair\\u2014and whether a high-resolution structure explains its non-catalytic specificity and acetylation-dependent switching remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No high-resolution structure of human ADA2-ADA3-GCN5 core\", \"Unified model linking transcriptional and centromeric/repair roles absent\", \"Direct substrate scope of ADA3-containing complexes in vivo incompletely mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [7, 11, 14, 15, 20]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [6, 27]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [2, 6, 14]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [26]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [16, 17]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [16, 26]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [9, 11, 14]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [6, 11, 14, 20]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [6, 16, 27]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [21, 26, 29]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [22]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [7, 24]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [8, 18, 19, 25]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [15, 28]}\n    ],\n    \"complexes\": [\"SAGA/ADA HAT complex\", \"PCAF complex\", \"TFTC\", \"ADA2-ADA3-GCN5 core\"],\n    \"partners\": [\"GCN5\", \"ADA2/TADA2A\", \"p300\", \"PCAF\", \"p53\", \"ESR1\", \"RARA\", \"CENP-B\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}